Physician profile
Marc E Chapman
NPI 1679578777
$3,125.11
in general payments reported to CMS, 2019-2025
42 companies · $627 in 2025
The $627 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $213 · 2021: $415 · 2022: $359 · 2023: $462 · 2024: $422 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.78 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $393.02 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $258.78 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $165.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $158.39 | 2022-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $129.13 | 2019 | |
| Lilly USA, LLC | $122.82 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Allergan, INC. | $120.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.68 | 2019-2025 | Jardiance |
| Amgen INC. | $107.90 | 2022-2025 | Repatha, Krystexxa, Otezla |
| Next Science LLC | $103.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $78.38 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $76.62 | 2019-2025 | Airsupra |
| Exact Sciences Corporation | $53.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.50 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.